PhenoPath, PLLC is a physician-owned specialty pathology practice and reference laboratory providing diagnostic and contract research services to pathology and oncology practices, hospitals, biopharmaceutical companies and research institutions in the U.S., Canada and around the world.
PhenoPath’s test menu includes a broad array of state-of-the-art immunohistochemistry, flow cytometry, fluorescence in situ hybridization and molecular assays as well as chromosome analysis.
PhenoPath now offers EGFR mutation testing using cell-free DNA isolated from plasma. Please see the links below for more information:
Please see Biomarker Testing for Checkpoint Inhibitors for more information on PD-L1 22C3, PD-L1 28-8 and PD-L1 SP142.
Your satisfaction with our services and offerings is a high priority for us, and we want to ensure that all of your needs are being met. By...Read More »
PhenoPath is proud to announce the release of FDA-approved PD-L1 IHC 22C3 pharmDx, for the semi-quantitative assessment of PD-L1 expression in non-small...Read More »
PhenoPath is pleased to offer the Roche cobas® EGFR Mutation Test (v2), the only FDA-approved IVD assay for the detection of T790M, Exon 19...Read More »